Charles River Laboratories International, Inc.

NYSE:CRL Stock Report

Market Cap: US$9.5b

Charles River Laboratories International Future Growth

Future criteria checks 1/6

Charles River Laboratories International is forecast to grow earnings and revenue by 12.1% and 4.4% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 11.9% in 3 years.

Key information

12.1%

Earnings growth rate

11.9%

EPS growth rate

Life Sciences earnings growth17.7%
Revenue growth rate4.4%
Future return on equity11.9%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Aug 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Recent updates

Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?

Dec 11
Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle

Nov 19

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 26
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Oct 11
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You

Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

Sep 10
Why Charles River Laboratories International, Inc. (NYSE:CRL) Could Be Worth Watching

US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Aug 10
US$227: That's What Analysts Think Charles River Laboratories International, Inc. (NYSE:CRL) Is Worth After Its Latest Results

Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)

Aug 10

Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Jul 26
Charles River Laboratories International (NYSE:CRL) Takes On Some Risk With Its Use Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Jul 11
Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)

Charles River Laboratories: Fair Valuation Against Fundamentals

May 31

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

May 25
What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Apr 27
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Apr 11
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Jan 17
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Jan 02
Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Earnings and Revenue Growth Forecasts

NYSE:CRL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,37245441473815
12/31/20254,10734235965117
12/31/20244,03230236265916
9/28/20244,061413560796N/A
6/29/20244,078432487750N/A
3/30/20244,112439414704N/A
12/30/20234,129475365684N/A
9/30/20234,216475368698N/A
7/1/20234,178484289625N/A
4/1/20234,092496275626N/A
12/31/20223,976486295620N/A
9/24/20223,781436280614N/A
6/25/20223,688443338656N/A
3/26/20223,630422412693N/A
12/25/20213,540391532761N/A
9/25/20213,426397452670N/A
6/26/20213,273396484672N/A
3/27/20213,041375479648N/A
12/26/20202,924364380547N/A
9/26/20202,824301446589N/A
6/27/20202,749271416567N/A
3/28/20202,724248385535N/A
12/28/20192,621252340481N/A
9/28/20192,532231295440N/A
6/29/20192,449219269402N/A
3/30/20192,377227264393N/A
12/29/20182,266225297437N/A
9/29/20182,143135321421N/A
6/30/20182,022128N/A363N/A
3/31/20181,906129N/A342N/A
12/30/20171,858123N/A316N/A
9/30/20171,846198N/A310N/A
7/1/20171,807183N/A323N/A
4/1/20171,772164N/A303N/A
12/31/20161,681154N/A315N/A
9/24/20161,568143N/A299N/A
6/25/20161,492143N/A315N/A
3/26/20161,398156N/A321N/A
12/26/20151,363150N/A305N/A
9/26/20151,339146N/A284N/A
6/27/20151,317140N/A263N/A
3/28/20151,319127N/A234N/A
12/27/20141,298128N/A251N/A
9/27/20141,257120N/A214N/A
6/28/20141,222119N/A214N/A
3/29/20141,174111N/A205N/A
12/28/20131,166104N/A207N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRL's forecast earnings growth (12.1% per year) is above the savings rate (2.6%).

Earnings vs Market: CRL's earnings (12.1% per year) are forecast to grow slower than the US market (15.3% per year).

High Growth Earnings: CRL's earnings are forecast to grow, but not significantly.

Revenue vs Market: CRL's revenue (4.4% per year) is forecast to grow slower than the US market (9.2% per year).

High Growth Revenue: CRL's revenue (4.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CRL's Return on Equity is forecast to be low in 3 years time (11.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:55
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Charles River Laboratories International, Inc. is covered by 45 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Gregory BolanAvondale Partners
Eric ColdwellBaird